Ignite Creation Date:
2025-12-24 @ 5:38 PM
Ignite Modification Date:
2026-02-28 @ 11:20 AM
Study NCT ID:
NCT02363868
Status:
COMPLETED
Last Update Posted:
2015-07-07
First Post:
2015-02-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-02
Start Date Type:
None
Primary Completion Date:
2014-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-11
Completion Date Type:
ACTUAL
First Submit Date:
2015-02-10
First Submit QC Date:
None
Study First Post Date:
2015-02-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-07-03
Last Update Post Date:
2015-07-07
Last Update Post Date Type:
ESTIMATED